Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma

Journal of Korean Medical Science

Volumn 21, Issue 4, 2006, Pages 639-644

  Yun, Jae Pil ^a   Suh, Cheolwon ^a   Lee, Eunkyoung ^b   Jai, Won Chang ^a   Won, Seok Yang ^a   Jung, Sik Park ^a   Park, Su Kil ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Dankook University   (South Korea)

Author keywords

Beta 2 Microglobulin; Glomerular Filtration Rate; Multiple Myeloma

Indexed keywords

EID: 33746905445     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.4.639     Document Type: Review

References (13)

1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-54.
2. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ; Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441-50.
3. Cuzick J, Cooper EH, MacLennan IC. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer 1985; 52: 1-6.
4. Alexanian R, Barlogie B, Fritsche H. Beta 2 microglobulin in multiple myeloma. Am J Hematol 1985; 20: 345-51.
5. Scarffe JH, Anderson H, Palmer MK, Crowther D. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma. Eur J Cancer Clin Oncol 1983; 19: 1361-4.
6. Bataille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment; a prospective study of 160 patients. Blood 1984; 63: 468-76.
7. Cuzick J, De Stavola BL, Cooper EH, Chapman C, MacLennan IC. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. Br J Haematol 1990; 75: 506-10.
8. Donadio C, Lucchesi A, Ardini M, Giordani R. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal 2001; 24: 835-42.
9. Jovanovic D, Krstivojevic P, Obradovic I, Durdevic V, Dukanovic L. Serum cystatin C and beta2-microglobulin as markers of glomerular filtration rate. Ren Fail 2003; 25: 123-33.
10. Bianchi C, Donadio C, Tramonti G, Consani C, Lorusso P, Rossi G. Reappraisal of serum beta2-microglobulin as marker of GFR. Ren Fail 2001; 23: 419-29.
11. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-57.
12. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY; Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-71.
13. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-7.